Oculis Shares Rise After Therapy Receives Breakthrough Designation from FDA

Dow Jones

01/06

By Connor Hart

Shares of Oculis climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration.

The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year.

The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies.

The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis.

Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. "Oculis is uniquely positioned to reshape the treatment landscape in areas with substantial unmet needs, and 2026 is shaping up to be a milestone-rich year across our late-stage portfolio," he added.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 06, 2026 06:52 ET (11:52 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2601891218"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601891218\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601891218?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 19:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601891218","market":"other","top_or_hot":-1,"title":"Oculis Shares Rise After Therapy Receives Breakthrough Designation from FDA","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/OCS\">Oculis</a> climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration. \n</p>\n<p>\n  The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year. \n</p>\n<p>\n  The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies. \n</p>\n<p>\n  The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis. \n</p>\n<p>\n  Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. \"Oculis is uniquely positioned to reshape the treatment landscape in areas with substantial unmet needs, and 2026 is shaping up to be a milestone-rich year across our late-stage portfolio,\" he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 06:52 ET (11:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oculis Shares Rise After Therapy Receives Breakthrough Designation from FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOculis Shares Rise After Therapy Receives Breakthrough Designation from FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-06 19:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/OCS\">Oculis</a> climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration. \n</p>\n<p>\n  The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year. \n</p>\n<p>\n  The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies. \n</p>\n<p>\n  The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis. \n</p>\n<p>\n  Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. \"Oculis is uniquely positioned to reshape the treatment landscape in areas with substantial unmet needs, and 2026 is shaping up to be a milestone-rich year across our late-stage portfolio,\" he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 06:52 ET (11:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601891218","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601891218","pubTimestamp":1767700320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Oculis climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration.The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year.The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies.The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis.Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. \"Oculis is uniquely positioned t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","OCS":"Oculis"},"translate_title":"Oculis疗法获得FDA突破性认定后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCS":1.5},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Oculis climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration. \n\n\n  The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year. \n\n\n  The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies. \n\n\n  The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis. \n\n\n  Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. \"Oculis is uniquely positioned to reshape the treatment landscape in areas with substantial unmet needs, and 2026 is shaping up to be a milestone-rich year across our late-stage portfolio,\" he added. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 06:52 ET (11:52 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}